| ID | 69889 |
| FullText URL | |
| Author |
Sue, Mihiro
Department of Diabetology and Metabolism, NHO Okayama Medical Center
Watanabe, Mayu
Department of Diabetology and Metabolism, NHO Okayama Medical Center
Inoue, Ayumi
Department of Diabetology and Metabolism, NHO Okayama Medical Center
Katayama, Akihiro
Department of Diabetology and Metabolism, NHO Okayama Medical Center
Teshigawara, Sanae
Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital
Matsushita, Yuichi
Department of Diabetology and Metabolism, NHO Okayama Medical Center
Takeda, Masaya
Department of Diabetology and Metabolism, NHO Okayama Medical Center
Iseda, Izumi
Department of Diabetology and Metabolism, NHO Okayama Medical Center
Eguchi, Jun
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
Hida, Kazuyuki
Department of Diabetology and Metabolism, NHO Okayama Medical Center
|
| Abstract | This report describes the first case of maturity-onset diabetes in young (MODY) with HNF1B mutation started administration of the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, tirzepatide. A 26-year-old female with a 15-year history of diabetes mellitus was diagnosed with MODY, which is characterized by decreased insulin secretion. She was treated with tirzepatide, which significantly improved her glycemic management; insulin secretion increased the fasting serum C-peptide immunoreactivity from 0.36 to 1.09 ng/mL. The patient discontinued glimepiride, and her total daily insulin dose was reduced from 88 to 4 units. This report highlights the glucose-lowering effects of tirzepatide in a patient with MODY who has the HNF1B p.Glu105Lys mutation.
|
| Keywords | glucagon-like peptide-1 (GLP-1)
glucose-dependent insulinotropic polypeptide (GIP)
maturity-onset diabetes in young (MODY)
tirzepatide
|
| Published Date | 2025-02
|
| Publication Title |
Clinical Case Reports
|
| Volume | volume13
|
| Issue | issue2
|
| Publisher | Wiley
|
| Start Page | e70173
|
| ISSN | 2050-0904
|
| Content Type |
Journal Article
|
| language |
English
|
| OAI-PMH Set |
岡山大学
|
| Copyright Holders | © 2025 The Author(s).
|
| File Version | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| Related Url | isVersionOf https://doi.org/10.1002/ccr3.70173
|
| License | http://creativecommons.org/licenses/by-nc-nd/4.0/
|
| Citation | Sue, M., Watanabe, M., Inoue, A., Katayama, A., Teshigawara, S., Matsushita, Y., Takeda, M., Iseda, I., Eguchi, J. and Hida, K. (2025), Maturity-Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report. Clin Case Rep, 13: e70173. https://doi.org/10.1002/ccr3.70173
|
